Official close
$48.17
−$1.69 · −3.39%
Boston Scientific Drops 3.4%, $2.5 Billion Value Lost Following Global Cyberattack
MARLBOROUGH, Massachusetts, August 27, 2026, 04:10 – Shares in Boston Scientific slid 3.4%, wiping out $2.5 billion in market value, after the company was affected by a worldwide cyberattack.
Boston Scientific · NYSE:BSX
Cyberattack investor dashboard
Order processing and customer shipments disrupted worldwide
Market data: August 26, 2026 close, EDT
Premarket: August 27, 2026, 04:01 EDT
Premarket: August 27, 2026, 04:01 EDT
Premarket
$48.40
+$0.23 · +0.48%
04:01 EDT, Aug. 27
Volume
36.56M
1.73× three-month average
Value erased
≈$2.49B
$1.69 × 1.4748B diluted shares
The market repriced restoration risk
The close recovered 2.71% from the intraday low but remained 3.39% below the prior close.
Q3 sales exposure: scenario, not forecast
Guided midpoint $5.268B
× Evercore growth-impact scenario 6%–7%
= $316M–$369M
× Evercore growth-impact scenario 6%–7%
= $316M–$369M
Evercore’s estimate is a 600–700 basis-point hit to third-quarter revenue growth. Boston Scientific has not quantified an impact.
Why the $2.49B selloff is notable
6.8×–7.9×
The estimated equity-value loss divided by the $316M–$369M sales scenario.
The gap prices more than deferred sales. It also reflects uncertainty around margins, remediation, customers, regulation and data exposure.
Operating baseline before the attack
| Metric | Latest figure | Growth / margin | Investor signal |
|---|---|---|---|
| Q2 2026 net sales | $5.442B | +7.5% reported | Growth exceeded Q3’s 3%–5% guide |
| Cardiovascular sales | $3.624B | +8.3% | 66.6% of Q2 revenue |
| MedSurg sales | $1.818B | +5.9% | 33.4% of Q2 revenue |
| Gross profit | $3.848B | 70.7% margin | Expedited freight or remediation could pressure margin |
| Adjusted EPS | $0.86 | FY guide $3.28–$3.32 | Guidance risk depends on restoration time |
Valuation and expectations
| Market capitalization | $69.81B |
| Trailing P/E | 20.2× |
| Forward P/E | 15.2× |
| Enterprise value / revenue | 4.02× |
| Average analyst target | $62.69 |
| Implied upside to close | 30.1% |
Valuation metrics were reported as of August 25; market capitalization uses the August 26 close. Consensus target: 31 analysts.
Peer-session context
August 26 official closes. The wider BSX decline points to company-specific incident risk.
Risks still unpriced precisely
Restoration Deferred sales Data exposure RegulationThe company has not identified the attacker, disclosed whether protected information was accessed, or estimated the financial impact. Longer disruption could add freight, remediation and support costs.
Comparable event
≈1 month
Stryker’s March 2026 attack disrupted order processing, manufacturing and shipping. Most manufacturing returned in about two weeks; full restoration followed roughly one month after detection. Stryker later expected no material 2026 guidance impact.
Boston Scientific Shares Drop 4.1% After Cyberattack Threatens Up to $369 Million in Q3 Revenue
NEW YORK, August 26, 2026, 09:40 – Shares of Boston Scientific fell 4.1% after the company disclosed that a cyberattack may endanger as much as $369 million in third-quarter sales.
NYSE: BSX · Cyberattack monitor
Boston Scientific
Order-processing and shipment disruption meets a reduced 2026 growth outlook.
Market snapshot
Aug. 26, 2026 · 09:40:21 EDT
Aug. 26, 2026 · 09:40:21 EDT
Share price
$47.81
−4.11% · −$2.05
Open $47.00 · range $46.90–$48.53
Quoted value lost
$2.97B
Estimated from 1.45B shares outstanding
Q3 revenue guide
$5.22–$5.32B
3%–5% growth vs. Q3 2025
Revenue risk scenario
$316–$369M
Evercore: 600–700 bp if recovery mirrors Stryker
Market repricing versus modeled sales exposure
The stock-market loss equals roughly 8.0×–9.4× the analyst's modeled revenue exposure.
Market valueLow scenarioHigh scenario
What moved the stock
Company detects a cybersecurity incident.
Discloses global disruption, including systems that process and ship orders.
Shares open at $47.00, 5.74% below prior close.
BSX trades at $47.81, down 4.11%.
Operating base
| Metric | Q2 2026 | YoY |
|---|---|---|
| Total sales | $5.442B | +7.5% |
| Cardiovascular | $3.624B | +8.3% |
| MedSurg | $1.818B | +5.9% |
| Adjusted EPS | $0.86 | +14.7% |
| GAAP net income | $907M | +13.8% |
Guidance and valuation
| Signal | Current reading |
|---|---|
| FY26 sales growth | 5.5%–6.5% reported |
| FY26 adjusted EPS | $3.28–$3.32 |
| Q3 adjusted EPS | $0.80–$0.82 |
| P/E | 19.38× |
| Analyst consensus | Buy · 31 analysts |
| Average target | $62.69 · 31% upside |
Scenario frame
| Recovery path | Revenue effect | Investor implication |
|---|---|---|
| Faster than Stryker | Below $316M | More orders may shift within the quarter rather than disappear. |
| About three weeks | $316M–$369M | Evercore's 600–700 bp scenario; a guide cut becomes plausible. |
| Longer or broader | Above $369M | Margin pressure and customer disruption could outlast shipment delays. |
Risk check
Boston Scientific has not determined whether the incident is reasonably likely to be material. The full scope, recovery duration and any data loss remain unknown.
Watch next: recovery timetable, shipment resumption, order recapture, guidance update.
Sources: Boston Scientific Q2 2026 results; Reuters, Aug. 26, 2026; Google Finance quote at 09:40:21 EDT; StockAnalysis analyst consensus. The $316M–$369M range is a scenario calculation, not company guidance.
Boston Scientific Climbs 2% After Steep Decline, Regains 38% of Thursday’s Loss
Boston Scientific Corporation gained 2.03% on Friday, recovering under 40% of Thursday’s decline. Shares settled at $50.37 at 16:00:02 EDT. Trading volume was 31.76 million, surpassing the three-month average by 51.8%.
NYSE: BSX · Investor snapshot
Boston Scientific
Friday’s high-volume rebound recovered only part of Thursday’s selloff.
$50.37▲ 2.03%
Close · Aug. 21, 2026, 16:00:02 EDT
Weekly return
-2.82%
Aug. 14–21 close
Volume
31.76M
1.52× three-month average
Avg. target
$62.69
+24.46% implied upside
Market cap
$73.0B
Approx. +$1.45B Friday
Six-session tape
Close, USDFriday recovered 38% of Thursday’s $2.64 lossWeek: -2.82%
Q2 operating pulse
YoY| Measure | Q2 2026 | Growth |
|---|---|---|
| Net sales | $5.442B | +7.5% |
| Adjusted EPS | $0.86 | +14.7% |
| Cardiovascular | $3.624B | +8.3% |
| MedSurg | $1.818B | +5.9% |
Adjusted EPS beat the company’s $0.82–$0.84 range.
Analyst posture
31 analysts| Rating | Mar. | Aug. |
|---|---|---|
| Strong Buy | 24 | 18 |
| Buy | 10 | 8 |
| Hold | 0 | 5 |
| Sell | 0 | 0 |
Consensus remains Buy, though enthusiasm has narrowed since March.
Valuation range
1-year targetsAverage upside looks substantial, but the low target sits 12.65% below Friday’s close.
What could helpSustained trading above $50, stronger WATCHMAN uptake and clean Penumbra execution.
What could hurtU.S. electrophysiology competition, slower WATCHMAN demand and $0.06–$0.08 first-year deal dilution.
Boston Scientific (NYSE:BSX) shares fall as international growth offsets slower U.S. cardiac performance
NEW YORK, July 29, 2026, 09:00 EDT — Boston Scientific shares declined after the medical device maker’s strong overseas results helped balance a downturn in its U.S. cardiac business.
Amazon takes number one spot on 2026 Fortune 500; regional shifts seen
Amazon has taken the No. 1 spot on the 2026 Fortune 500, Fortune said, unseating Walmart after 13 years at the top. The change put Amazon ahead for the first time in more than a decade and drove shifts in regional tallies for Pennsylvania, New Jersey and New England. Fortune’s 72nd annual list put the collective revenue at $21.0 trillion, with profits at $2.1 trillion and a workforce of 30.5 million worldwide.
Boston Scientific Drops 16%. Next Up: Monday’s Watchman Reaction
Boston Scientific is starting the week trading close to its recent lows after shares dropped 16.4% last week. The selloff came as investors question if the slowdown in demand for its Watchman heart implant is temporary or a sign of a longer-term slowdown. The stock ended at $48.31 on May 29, down from $57.78 at the May 22 close, according to historical price data.
Boston Scientific Hits Two-Year Low After Watchman Device Warning
Boston Scientific’s stock dropped Wednesday after CEO Michael Mahoney said the company is seeing slower use of its Watchman heart device. The shares fell around 10% to $51.63 in recent trading, hitting a session low of $50.60, their lowest in over two years.
US Stock Market Today: Nasdaq Leads Wall Street Rally as Iran Ceasefire Relief Meets Earnings Momentum
U.S. stocks climbed Wednesday, with tech names pushing the Nasdaq higher, as investors returned to technology shares and snapped up companies posting strong earnings following President Donald Trump’s move to extend the ceasefire with Iran.
Boston Scientific stock price slips again: BSX extends slide as heart-rhythm worries linger
Boston Scientific was off 2.6% at $74.29 as of 11:50 a.m. EST Monday, slipping from an earlier session low of $74.12. Shares dropped even as the SPDR S&P 500 ETF Trust advanced roughly 0.6%.
Boston Scientific stock price slips again after earnings shock as BSX investors eye heart-rhythm sales
Boston Scientific Corp finished Friday at $76.27, down 1.8%. The stock barely moved after the bell, still near its post-earnings slump from earlier this week. Roughly 34.9 million shares changed hands.
Boston Scientific stock rebounds after earnings shock as analysts cut targets on EP worries
Boston Scientific shares climbed 2.8% Thursday, closing at $77.64. Trading volume hit roughly 38.3 million shares.
Boston Scientific stock rebounds after brutal selloff — what Wall Street watches next
Boston Scientific shares climbed roughly 3.3% on Thursday, recovering some losses after a steep drop the previous day shook investors concerned about the medical device maker’s 2026 outlook. The stock traded at $77.97 in afternoon trading.
Boston Scientific stock tries to steady after an 18% earnings drop put EP business on edge
Boston Scientific shares ticked up roughly 1% in Thursday’s premarket, recovering some ground after a sharp slide the previous day. The stock hovered near $76.30, up from Wednesday’s $75.50 close.
Boston Scientific (BSX) stock dives on electrophysiology sales miss — what to watch after the bell
Shares of Boston Scientific plunged Wednesday following a disappointing sales report from its electrophysiology division, a key growth driver closely watched by investors. The stock dropped $16.23, or roughly 17.7%, to $75.50 in after-hours trading.
Boston Scientific stock price skids as key heart-rhythm sales miss jolts BSX
Boston Scientific shares dropped sharply on Wednesday, falling roughly 15% to $77.83 following a quarterly sales report that fell short of expectations in its electrophysiology segment.
Boston Scientific stock slips today: what to know before earnings and key Watchman trial data
Boston Scientific dipped about 0.7% to $91.20 in afternoon action Tuesday, after swinging between $93.01 and $90.85. Roughly 10.4 million shares traded.
Boston Scientific stock price drops today: BSX slides as investors size up Feb. 4 earnings, Watchman trial date
Boston Scientific shares dropped roughly 1.6% to $92.01 in Monday afternoon trading, bouncing between $94.13 and $91.64 earlier. The stock underperformed peers Abbott Laboratories, Medtronic Plc, and Stryker Corp., even as the S&P 500 ETF Trust climbed higher.
Boston Scientific stock snaps a 4-day run — what to watch before Feb. 4 earnings
Shares of Boston Scientific Corp closed Thursday roughly 1.6% lower at $92.33, having fluctuated between $91.48 and $94.25 during the session.
ISRG stock slips after FDA clears da Vinci 5 for heart procedures; TD Cowen starts at Buy
Shares of Intuitive Surgical, Inc. slipped 0.7% to $525.09 Tuesday, despite a fresh U.S. approval for its newest da Vinci 5 surgical robot. Meanwhile, the broader market moved higher, with the S&P 500 ETF gaining roughly 0.5% and the Nasdaq-focused QQQ rising about 0.9%.
Boston Scientific (BSX) stock ticks higher again — what to watch before Tuesday’s trade
Shares of Boston Scientific Corp climbed 1.12% to $93.55 on Monday, while the S&P 500 edged up 0.50% and the Dow Jones Industrial Average gained 0.64%. The stock underperformed Abbott Laboratories and Stryker but outpaced Medtronic. Trading volume stayed above its 50-day average. Despite Monday’s gain, shares remain roughly 14.6% below their 52-week peak from September.
TechStock² Updates
